Essex Investment Management Co. LLC Takes Position in Beta Bionics, Inc. $BBNX

Essex Investment Management Co. LLC bought a new stake in Beta Bionics, Inc. (NASDAQ:BBNX) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 222,615 shares of the company’s stock, valued at approximately $4,423,000. Essex Investment Management Co. LLC owned 0.51% of Beta Bionics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GPS Wealth Strategies Group LLC boosted its holdings in Beta Bionics by 45.0% in the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Beta Bionics by 10.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,558 shares of the company’s stock worth $343,000 after purchasing an additional 2,205 shares during the period. Strs Ohio bought a new position in shares of Beta Bionics in the 1st quarter worth $29,000. Legal & General Group Plc lifted its holdings in shares of Beta Bionics by 197.4% in the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after purchasing an additional 2,639 shares in the last quarter. Finally, CWM LLC acquired a new stake in Beta Bionics in the 2nd quarter valued at $58,000.

Wall Street Analysts Forecast Growth

BBNX has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Beta Bionics in a report on Monday, December 29th. Truist Financial lowered their target price on shares of Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. UBS Group assumed coverage on shares of Beta Bionics in a research report on Sunday. They issued a “buy” rating and a $24.00 price target on the stock. Piper Sandler reissued an “overweight” rating and set a $32.00 price objective (up from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Finally, Robert W. Baird set a $28.00 target price on Beta Bionics in a report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $26.42.

Beta Bionics Stock Performance

Beta Bionics stock opened at $13.87 on Tuesday. Beta Bionics, Inc. has a fifty-two week low of $8.89 and a fifty-two week high of $32.71. The firm’s 50-day simple moving average is $23.92 and its 200 day simple moving average is $22.66. The stock has a market cap of $610.70 million and a PE ratio of -3.17.

Insider Activity at Beta Bionics

In related news, insider Mike Mensinger sold 7,800 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $29.61, for a total transaction of $230,958.00. Following the completion of the sale, the insider directly owned 82,952 shares of the company’s stock, valued at approximately $2,456,208.72. This trade represents a 8.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Stephen Feider sold 20,000 shares of Beta Bionics stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the sale, the chief financial officer owned 42,614 shares in the company, valued at $1,258,391.42. This trade represents a 31.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 32,490 shares of company stock valued at $960,835.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.